Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prenetics Global Limited filings document a foreign private issuer that furnishes Form 6-K reports for material corporate updates, financial results and press-release exhibits. The filings cover the company’s IM8 consumer health and longevity business, including product and partnership announcements, operating results, registration-statement incorporation and disclosures tied to its focus on global expansion of the brand.
The filing record also documents capital allocation and governance matters, including Class A Ordinary Share repurchase authorization, executive open-market share purchases, board changes, treasury policy related to digital assets and completed divestiture activity such as the sale of the company’s Insighta equity interest. These disclosures frame Prenetics’ capital structure, liquidity commentary and reported business priorities as a public foreign issuer.
Prenetics Global Limited filed a Form 6‑K furnishing a press release with its unaudited financial results for the third quarter ended September 30, 2025. The filing states that this report is incorporated by reference into the company’s existing Form F‑3 and Form S‑8 registration statements. The press release is attached as Exhibit 99.1.
Prenetics Global Limited closed a best efforts public offering of 2,722,642 Class A ordinary shares, each sold together with one Class A warrant and one Class B warrant at a combined price of $16.08 per unit. The company reported gross proceeds of approximately $44 million.
The Class A and Class B warrants are immediately exercisable for up to 2,722,642 shares each at exercise prices of $24.12 and $32.16, respectively, and have a five-year term from closing. Dominari Securities LLC acted as sole placement agent; compensation was an 8% cash success fee (reduced to 4% for company-introduced investors). Prenetics also issued placement agent warrants to purchase 131,829 shares at $16.08.
Prenetics plans to use proceeds for global expansion of IM8, development and implementation of its Bitcoin treasury strategy, working capital, and general corporate purposes. The transaction was conducted under an effective Form F-3 and closed on October 28, 2025.
Prenetics Global Limited launched a primary offering of 2,722,642 Class A Ordinary Shares at $16.08 per share sold together with one Class A warrant and one Class B warrant, plus warrants to purchase up to 5,445,284 shares and Placement Agent Warrants to purchase up to 131,829 shares. Gross proceeds are $43,779,297.56 with estimated net proceeds of $40.1 million.
Each Class A warrant is exercisable at $24.12 and each Class B warrant at $32.16, both immediately exercisable and expiring five years from issuance; the warrants will not be listed and may have limited liquidity. Dominari Securities LLC acted as exclusive placement agent with fees of 8% (reduced to 4% for certain investors) and warrant coverage. Shares outstanding were 12,524,823 Class A and 1,580,972 Class B prior to the offering and will be 15,247,465 Class A and 1,580,972 Class B immediately after.
The Company intends to use proceeds to expand IM8 globally, develop and implement its Bitcoin treasury strategy, and for working capital and general corporate purposes. The filing highlights risks including immediate dilution, lack of a trading market for the warrants, PFIC considerations, and Bitcoin-related volatility and custody risks.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing the pricing and subscription of its best efforts public offering. The press release is included as Exhibit 99.1. The report is signed by Chief Financial Officer Lo Hoi Chun on October 27, 2025.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing the pricing and subscription of its best efforts public offering. The press release is included as Exhibit 99.1. The report is signed by Chief Financial Officer Lo Hoi Chun on October 27, 2025.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer to provide an update for October 2025. The company states that on October 27, 2025 it issued a press release announcing the pricing of its best efforts public offering. The press release describing this offering is included with the report as Exhibit 99.1.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer to provide an update for October 2025. The company states that on October 27, 2025 it issued a press release announcing the pricing of its best efforts public offering. The press release describing this offering is included with the report as Exhibit 99.1.
Prenetics Global Limited launched a preliminary prospectus supplement for a primary offering of Class A Ordinary Shares and/or Pre-funded Warrants, each sold together with one Class A Warrant and one Class B Warrant. The Class A and Class B Warrants are exercisable immediately and will expire five years from issuance. The warrants and Pre-funded Warrants will be issued separately but are not being listed, so liquidity may be limited.
Dominari Securities LLC is engaged as exclusive placement agent on a reasonable best efforts basis, with cash fees of 8% of gross proceeds (reduced to 4% for company-introduced investors) and placement agent warrants equal to up to 6% of the securities sold (reduced to 2% for directed orders). Pre-funded Warrants are available to investors whose share purchases would otherwise exceed 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership. Net proceeds are intended for IM8 global expansion, development and implementation of the Company’s Bitcoin treasury strategy, working capital and general corporate purposes.
Prenetics Global Limited launched a preliminary prospectus supplement for a primary offering of Class A Ordinary Shares and/or Pre-funded Warrants, each sold together with one Class A Warrant and one Class B Warrant. The Class A and Class B Warrants are exercisable immediately and will expire five years from issuance. The warrants and Pre-funded Warrants will be issued separately but are not being listed, so liquidity may be limited.
Dominari Securities LLC is engaged as exclusive placement agent on a reasonable best efforts basis, with cash fees of 8% of gross proceeds (reduced to 4% for company-introduced investors) and placement agent warrants equal to up to 6% of the securities sold (reduced to 2% for directed orders). Pre-funded Warrants are available to investors whose share purchases would otherwise exceed 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership. Net proceeds are intended for IM8 global expansion, development and implementation of the Company’s Bitcoin treasury strategy, working capital and general corporate purposes.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing a proposed public offering. The company states that the press release, dated October 24, 2025, is provided as Exhibit 99.1 to this report.
The filing lists the exhibit and includes the company’s authorization by Chief Financial Officer Lo Hoi Chun.
Prenetics Global Limited furnished Amendment No. 1 to Form 6-K, adding its condensed consolidated financial statements for the six months ended June 30, 2025 as Exhibit 99.2. The amendment supplements the September 12, 2025 Form 6-K that included business updates and unaudited Q2 results and does not change other information. This report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Prenetics Global Limited filed Amendment No. 2 to its Form 6-K to update the risk disclosure tied to its bitcoin treasury strategy. The amendment replaces and supersedes the prior Exhibit 99.1 in an earlier Form 6-K/A, which itself had replaced the original Form 6-K risk factor exhibit. Other disclosures in the earlier Form 6-K and Form 6-K/A remain unchanged. The filing also reiterates that statements about expectations and future performance are forward-looking and subject to significant risks and uncertainties referenced in the company’s Form 20-F and other SEC filings.